Registration Statement on Form F-4 Filed With the SEC
Shares Expected to be Approved for Listing on NASDAQ in H1 2008
HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/ --
- Compilation of IFRS Financial Information Resulted in Adjustments of Evotec's Consolidated Financial Statements With a Positive Net Effect on the Accumulated Deficit of EUR23.7 Million as of September 30 2007
Evotec AG (Frankfurt Stock Exchange: EVT) today provided further details on its planned NASDAQ listing in the context of the anticipated acquisition of Renovis Inc. Evotec AG has filed a registration statement on Form F-4 to register with the US Securities and Exchange Commission (SEC) the Evotec AG ordinary shares. These shares underlie the Evotec AG American Depositary Shares, or ADSs, that Renovis stockholders will receive in connection with the proposed merger. The Evotec ADSs are expected to be approved for listing on the NASDAQ Global Market under the trading symbol "EVTC" in H1 2008. JPMorgan Chase Bank, N.A., as the depositary will issue the ADSs.
In the process of compiling financial information, that is required to
be filed with the SEC as part of the registration statement, the Company
has retrospectively adjusted the representation of the ENS Holdings, Inc.
acquisition under International Financial Reporting Standards (IFRS). In
its previously filed consolidated financial statements under IFRS for the
year ended December 31, 2005 the Company had capitalized and immediately
impaired the portion of the purchase price allocated to goodwill in the
amount of EUR 18.5 million, which resulted in a charge in that amount
against earnings. Following a review of the accounting of the business
combination, this amount has now been re-evaluated and allocated mainly to
developed technologies acquired ("In-process Research and Development") in
the amount of EUR 38.5 million, in particular to Evotec's clinical programs
|SOURCE Evotec AG|
Copyright©2008 PR Newswire.
All rights reserved